Filtered By:
Drug: Cilostazol

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 208 results found since Jan 2013.

An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats.
Authors: Yoshioka C, Ito Y, Nagai N Abstract Cilostazol (CLZ) is an anti-platelet agent that is generally used after the onset of cerebral infarction. However, CLZ is a poorly water-soluble drug and a strategy for increasing its bioavailability is required. In the present study, novel oral formulations were designed containing CLZ solid nanoparticles to improve bioavailability. The present study investigated the therapeutic effect of the oral formulations containing CLZ nanoparticles on ischemic stroke using a cerebral ischemia/reperfusion-induced injury model (MCAO/reperfusion mice). The oral formulation containin...
Source: Experimental and Therapeutic Medicine - January 30, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

The response of carotid intima-media thickness to medical treatment is correlated with that of intracranial atherosclerosis.
CONCLUSIONS: The ICAS response may be associated with the CIMT response to medical treatment. PMID: 24285964 [PubMed]
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials
Abstract The aim of this study was to obtain best estimates of the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and cilostazol) compared with dual antiplatelet therapy (DAPT: aspirin and clopidogrel) in patients undergoing coronary stent implantation. We searched the literature to identify all randomized clinical trials examining efficacy and safety of TAPT versus DAPT in patients undergoing coronary stent implantation. Major efficacy outcomes were death, non-fatal myocardial infarction (MI), ischemic stroke and stent thrombosis (ST) and the safety outcome was bl...
Source: Journal of Thrombosis and Thrombolysis - January 1, 2015 Category: Hematology Source Type: research

Cilostazol: An Option for Ischemic Stroke After ICH? Cilostazol: An Option for Ischemic Stroke After ICH?
The antiplatelet agent cilostazol showed promising results among this difficult-to-treat group in the PICASSO trial.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - March 2, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Platelet-Derived Growth Factor Is Associated with Progression of Symptomatic Intracranial Atherosclerotic Stenosis.
CONCLUSIONS: The PDGF-AB/BB level is associated with the progression of ICAS, and so may play a significant role in the progression of human ICAS. PMID: 33480201 [PubMed]
Source: Journal of Clinical Neurology - January 24, 2021 Category: Neurology Tags: J Clin Neurol Source Type: research

Factors Influencing Long-Term Blood Flow in Extracranial-to-Intracranial Bypass for Symptomatic Internal Carotid Artery Occlusive Disease: A Quantitative Study
CONCLUSION: Double anastomoses and cilostazol resulted in long-term STA blood flow preservation. No recurrence of cerebral infarction was noted in either STA hypoperfusion or occlusion cases.
Source: Neurosurgery - March 24, 2022 Category: Neurosurgery Tags: Research—Human—Clinical Studies: Cerebrovascular Source Type: research

Medical management of critical limb ischaemia: where do we stand today?
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - June 26, 2013 Category: Internal Medicine Authors: Matthew A. Lambert, Jill J. F. Belch Tags: Review Source Type: research

Efficacy of Cilostazol in Preventing Aspiration Pneumonia in Acute Cerebral Infarction
This retrospective study examined the effectiveness of cilostazol in preventing aspiration pneumonia in patients with acute cerebral infarction. The 189 subjects ranged in age from 31 to 95 years and included 57 with small-artery occlusion, 107 with large-artery atherothrombosis, and 25 with other disorders. Patients with cardiogenic cerebral embolism or preexisting pneumonia at the time of hospital admission were excluded from the analysis. Neurologic symptoms, cognitive function, and swallowing function were assessed at the first clinical examination, and the ability to perform activities of daily living was assessed at ...
Source: Journal of Stroke and Cerebrovascular Diseases - August 9, 2012 Category: Neurology Authors: Aiko Osawa, Shinichiro Maeshima, Norio Tanahashi Tags: Original Articles Source Type: research

Neurovascular protection of cilostazol in stroke‐prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation
This study sought to evaluate the effects of commonly used antiplatelet drugs on spontaneous cerebral infarction in relation to neurovascular protection associated with angiogenesis and pericyte proliferation. Stroke‐prone spontaneously hypertensive rats (SHR‐SP) were treated with vehicle, aspirin, clopidogrel, or cilostazol from 8 to 10 weeks of age. The interaction of neurovascular components among endothelial cells, pericytes, and astrocytic endfeet were immunohistochemically examined in brain sections. Angiogenesis associated with vascular endothelial growth factor receptor 2 (VEGFR2) and pericyte proliferation wer...
Source: Journal of Neuroscience Research - December 21, 2013 Category: Neuroscience Authors: Yoshio Omote, Kentaro Deguchi, Syoichiro Kono, Ning Liu, Wentao Liu, Tomoko Kurata, Toru Yamashita, Yoshio Ikeda, Koji Abe Tags: Research Article Source Type: research

Efficacy of Cilostazol in Prevention of Bradycardia during Carotid Artery Stenting
Conclusion: Use of cilostazol was associated with a lower incidence of IBc. Cilostazol may be a useful drug for the prevention of this complication.
Source: Journal of Stroke and Cerebrovascular Diseases - July 8, 2013 Category: Neurology Authors: Daizo Ishii, Tetsu Satow, Kenichi Murao, Kunihiro Nishimura, Koji Iihara Tags: Original Articles Source Type: research

Cilostazol Inhibits Platelet–Endothelial Cell Interaction in Murine Microvessels after Transient Bilateral Common Carotid Artery Occlusion
Background: The purpose of this study was to investigate the effects of cilostazol on platelet behavior (rolling and adhesion) in murine cerebral microvessels after transient bilateral carotid artery occlusion using intravital fluorescence microscopy.Methods: We used 41 C57BL/6J mice for the experiment. Fourteen mice were used as sham group (no ischemia and reperfusion, no medication); an ischemia (induced by 15-minute occlusion of bilateral common carotid arteries) and reperfusion (I/R) group (n = 17); and an I/R + cilostazol (I/R + CZ) group (receiving 30 mg/kg of cilostazol orally at 30 minutes before ischemia) ...
Source: Journal of Stroke and Cerebrovascular Diseases - October 16, 2013 Category: Neurology Authors: Takuya Fukuoka, Takeshi Hayashi, Makiko Hirayama, Hajime Maruyama, Norio Tanahashi Tags: Original Articles Source Type: research

Do the Antithrombotic Therapy at the Time of Intracerebral Hemorrhage Influence Clinical Outcome? Analysis between the Difference of Antiplatelet and Anticoagulant Agents and Clinical Course
Background: It is controversial whether taking antiplatelet agents (APs) or anticoagulant agents (ACs) could influence clinical outcome after intracerebral hemorrhage (ICH).Methods: We retrospectively investigated 557 ICH patients between September 2008 and August 2013. We reviewed patients' characteristics, hematoma volume, deterioration (hematoma expansion, surgical hematoma evacuation, or death), and clinical outcome in modified Rankin Scale.Results: A total of 397 were classified as neither AP nor AC (“Nothing”), 81 as single AP (44 as aspirin [ASA], 22 as clopidogrel or ticlopidine [CLP/TIC], 7 as cilostazol, 8 as...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Takeshi Okada, Taizen Nakase, Masahiro Sasaki, Tatsuya Ishikawa Tags: Original Articles Source Type: research

Carotid Plaque Characteristics on Magnetic Resonance Plaque Imaging Following Long-term Cilostazol Therapy
Conclusions: Signal alterations on MR plaque imaging indicated the increase of fibrous components and the decrease of lipid/necrotic components in the carotid plaque during the cilostazol therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - August 29, 2014 Category: Neurology Authors: Mao Yamaguchi Oura, Makoto Sasaki, Hideki Ohba, Shinsuke Narumi, Kazumasa Oura, Ikuko Uwano, Yasuo Terayama Tags: Original Articles Source Type: research

The Effect of Acute Medication with Cilostazol, an Anti-platelet Drug, on the Outcome of Small Vessel Brain Infarction
Source: Journal of Stroke and Cerebrovascular Diseases - February 10, 2014 Category: Neurology Authors: Taizen Nakase, Masahiro Sasaki, Akifumi Suzuki Tags: Original Articles Source Type: research

Cilostazol for intermittent claudication.
CONCLUSIONS: Cilostazol has been shown to be of benefit in improving walking distance in people with intermittent claudication secondary to PAD. Although there is an increase in adverse side effects, they are generally mild and treatable. There is currently insufficient data on whether taking cilostazol results in a reduction of all-cause mortality and cardiovascular events or an improvement in quality of life. Future research into the effect of cilostazol on intermittent claudication should carefully consider comparability, sample size and homogeneity when designing a study. PMID: 25358850 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 5, 2014 Category: Journals (General) Authors: Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G Tags: Cochrane Database Syst Rev Source Type: research